Golimumab is really a human monoclonal antibody administered after per month by subcutaneous injection. Regardless that it's got a similar security and efficacy profile to other TNFi, golimumab is significantly less helpful than other TNFi in individuals who have unsuccessful multiple biological treatments. attributes proceedings of national and international conferences https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/